Iovance Biotherapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
Iovance Biotherapeutics Stock Forecast and Price Target
In recent months, four notable analysts have provided yearlong price targets for Iovance Biotherapeutics, with the average target coming in at $25.50. If it were to be achieved, this would result in a potential upside of approximately 68.87 percent from the most recent closing price in March, 2024. The high end is $34.00, and the low is $18.00. Even if you are not interested in IOVA stock, you should still be aware of its competitors.
68.87% Upside
Iovance Biotherapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Iovance Biotherapeutics's Price has grown, increasing from $0.00 to $0.00 – a growth of 100.00%. The next year looks promising for Iovance Biotherapeutics, with analysts predicting Fair Value of $16.38 – an increase of 100.00%. Over the next seven years, experts anticipate that Iovance Biotherapeutics's Fair Value will grow at a rate of 100.00%.
Iovance Biotherapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last zero years, Iovance Biotherapeutics's Revenue has decreased by 0.00%, from $1.19M to $1.19M. The next year looks promising for Iovance Biotherapeutics, with analysts predicting Revenue of $190.19M – an increase of 15882.35%. Over the next seven years, experts anticipate that Iovance Biotherapeutics's Revenue will grow at a rate of 134787.39%.
Iovance Biotherapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Iovance Biotherapeutics's EBITDA has grown by 72.04%, rising from $-260.80M to $-448.68M. According to 2 major analysts, Iovance Biotherapeutics's EBITDA will fall by 16.81% in the next year, reaching $-373.25M. Professionals believe that By 2030, Iovance Biotherapeutics's EBITDA will fall to $-235.37M– a 47.54% decrease from its current value.
Iovance Biotherapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Iovance Biotherapeutics's EBIT has grown by 75.83%, rising from $-261.94M to $-460.56M. In the next year, 11 analysts estimate that Iovance Biotherapeutics's EBIT will decrease by 24.60%, reaching $-347.24M. According to professional forecasts, in 2030, Iovance Biotherapeutics's EBIT will decrease by 211.38%, reaching $512.98M.
Iovance Biotherapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Iovance Biotherapeutics's EPS has grown, increasing from $-1.88 to $0.00 – a growth of 100.00%. The next year looks promising for Iovance Biotherapeutics, with analysts predicting EPS of $-1.44 – an increase of 100.00%. Over the next seven years, experts anticipate that Iovance Biotherapeutics's EPS will grow at a rate of 100.00%.